Scynexis Inc (SCYX NASDAQ) stock market data APIs
$0.9454
0.03(3.2%)
as of May 5, 2026
Try our APIs with
free plan!
Scynexis Inc Financial Data Overview
Price chart is built with
Anychart
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Prev. Close
0.9454
Open
0.9712
High
1.0088
Low
0.9341
52 wk Range
0.565-1.31
Market Cap
74 906 K
Shares Outstanding
79 443 K
Revenue
20 601 K
EPS
0
Beta
1.121
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Scynexis Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Scynexis Inc data using free add-ons & libraries
Get Scynexis Inc Fundamental Data
Scynexis Inc Fundamental data includes:
- Net Revenue: 20 601 K
- EBITDA: -36 537 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-01
- EPS/Forecast: 0.1267
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Scynexis Inc News
New
Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up
(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 m...
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy
SCYNEXIS, Inc. (NASDAQ:SCYX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now.SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy On F...
SCYNEXIS Posts Narrower FY25 Loss, Advances Next-Gen Antifungal Pipeline
(RTTNews) - SCYNEXIS, Inc. (SCYX) has reported its full-year 2025 results, while highlighting progress across its antifungal pipeline, including its next-generation candidate SCY-247 and updates on it...
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
CERo Therapeutics Holdings, Inc. SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellula...
Get Scynexis Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
